Tonix Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 0/6
Tonix Pharmaceuticals Holding's earnings have been declining at an average annual rate of -32%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 105.4% per year.
Key information
-32.0%
Earnings growth rate
101.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 105.4% |
| Return on equity | -110.6% |
| Net Margin | -1,501.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Tonix stock rises on FDA nod to start trial of TNX-601 for depression
Oct 03Tonix Pharmaceuticals GAAP EPS of -$1.22 beats by $0.23
Aug 08Tonix announces partnership to study monkeypox vaccine in 1H 2023
Jul 28Tonix Pharma to develop extended-release form of depression therapy
Jul 11Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?
Jun 21Revenue & Expenses BreakdownBeta
How Tonix Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -117 | 35 | 87 |
| 30 Sep 23 | 4 | -123 | 31 | 94 |
| 30 Jun 23 | 0 | -124 | 30 | 95 |
| 31 Mar 23 | 0 | -123 | 30 | 90 |
| 31 Dec 22 | 0 | -117 | 30 | 82 |
| 30 Sep 22 | 0 | -112 | 29 | 79 |
| 30 Jun 22 | 0 | -102 | 27 | 70 |
| 31 Mar 22 | 0 | -98 | 26 | 72 |
| 31 Dec 21 | 0 | -92 | 23 | 69 |
| 30 Sep 21 | 0 | -80 | 21 | 59 |
| 30 Jun 21 | 0 | -73 | 19 | 54 |
| 31 Mar 21 | 0 | -64 | 17 | 47 |
| 31 Dec 20 | 0 | -52 | 14 | 36 |
| 30 Sep 20 | 0 | -46 | 12 | 30 |
| 30 Jun 20 | 0 | -42 | 12 | 26 |
| 31 Mar 20 | 0 | -34 | 11 | 19 |
| 31 Dec 19 | 0 | -31 | 11 | 18 |
| 30 Sep 19 | 0 | -31 | 10 | 18 |
| 30 Jun 19 | 0 | -28 | 10 | 16 |
| 31 Mar 19 | 0 | -29 | 9 | 16 |
| 31 Dec 18 | 0 | -29 | 9 | 18 |
| 30 Sep 18 | 0 | -24 | 8 | 16 |
| 30 Jun 18 | 0 | -24 | 8 | 17 |
| 31 Mar 18 | 0 | -23 | 8 | 16 |
| 31 Dec 17 | 0 | -21 | 8 | 13 |
| 30 Sep 17 | 0 | -23 | 9 | 15 |
| 30 Jun 17 | 0 | -25 | 9 | 15 |
| 31 Mar 17 | 0 | -30 | 9 | 21 |
| 31 Dec 16 | 0 | -39 | 10 | 29 |
| 30 Sep 16 | 0 | -45 | 12 | 33 |
| 30 Jun 16 | 0 | -50 | 13 | 39 |
| 31 Mar 16 | 0 | -52 | 13 | 39 |
| 31 Dec 15 | 0 | -48 | 13 | 36 |
| 30 Sep 15 | 0 | -44 | 12 | 32 |
| 30 Jun 15 | 0 | -38 | 11 | 27 |
| 31 Mar 15 | 0 | -32 | 10 | 22 |
| 31 Dec 14 | 0 | -28 | 9 | 19 |
| 30 Sep 14 | 0 | -22 | 8 | 14 |
| 30 Jun 14 | 0 | -18 | 7 | 11 |
| 31 Mar 14 | 0 | -14 | 7 | 7 |
| 31 Dec 13 | 0 | -11 | 6 | 5 |
| 30 Sep 13 | 0 | -10 | 5 | 4 |
Quality Earnings: TNXP is currently unprofitable.
Growing Profit Margin: TNXP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNXP is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare TNXP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNXP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: TNXP has a negative Return on Equity (-110.55%), as it is currently unprofitable.